is...Trying to learn the ropes in OTC World is like drinking from a firehose.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GodisGreat...
All The Time...
SLAM
August 29, 2017
Food and Drug Administration
Florida District Office
555 Winderley Place, Suite 200
Maitland, FL 32751
RE: Warning letter received August 24th, 2017
Dear Mr. Randall Morris,
Please accept this letter as response to the warning letter received August 24th, 2017. In sum, as was previously demonstrated, the US Stem Cell Clinic (USCC) is not utilizing a biological drug product and therefore the regulations of part 210 and 211 (current good manufacturing practices) do not apply. The comments in the provided warning letter are specific to products that are produced in cGMP manufacturing facilities and classified as drugs according to the FDA. This is not something that a medical clinic would be required to follow. USCC is not manufacturing a drug. That being said, in an abundance of caution, US Stem Cell Clinic will immediately switch to 510(k) approved systems to process tissue in clinic such as bone marrow systems and/or fat systems.
Our facility has demonstrated sterile surgical techniques as required by the medical boards. It is inappropriate and harmful to state that our clinic is not sterile as we are completely compliant with the regulations for surgical procedures including using individually wrapped disposable sterile supplies, sterile field prep, and more. The strict regulations mentioned in the warning letter required to manufacture drugs are not applied to clinics or hospitals. As a clinic performing a medical procedure, we have strict and appropriate protocols in place to prevent contamination and breach of sterility. We are following the exact protocols that are utilized at surgical centers and hospitals. As you know, these protocols are very different than what is required for GMP manufacturing facilities. We have never had an incidence of contamination and the statements that were made in your warning letter and press release are misleading and causing irreparable harm.
We have previously described in detail why the FDA has wrongly defined these in clinic procedures as a drug and provided evidence. The evidence and summary is provided below. I would like to specifically call your attention to the fact that according to your current code of federal regulations, same surgical procedure is not subject to the rules for tissue banks which include minimal manipulation and homologous use. We strongly believe that it is a violation of the rights of American citizens to prevent them from seeking alternative care for their conditions as long as it does not violate regulations or the law. Our clinic is not violating the law as it is currently written. There is huge support from government officials and American citizens for stem cell treatments—again, while all laws are adhered to as we do. Please refer to just one petition out of many regarding stem cell treatments in clinic with almost 70,000 signatures: https://www.change.org/p/fda-don-t-shut-down-our-access-to-needed-stem-cell-therapy-treatment.
We would also like to address the comment in your warning letter regarding our firm impairing the ability to conduct the inspection. This statement is blatantly false and should be removed from the record. We provided access to every room in the facility and allowed pictures on multiple occasions. We also provided copies of all requested documents including confidential patient information. We are an extremely small firm with only a handful of employees most of which are part time or 1099 contract. As a small firm with limited resources, it is necessary to schedule the access that was required by the investigators in order to prevent permanent damage to our business. We provided abundant time and availability to the inspectors and on several occasions, the inspectors canceled last minute and did not come. At one point, the inspectors came to the office when the office was closed. During this last inspection, we worked with the inspectors for over a month providing hundreds of copies and burned CDs. On several occasions, I requested paper, printer ink and office supplies but did not receive what was requested. This inspection caused undue financial harm to our small firm—yet we made our staff and resources available to the investigators at all times. Stating that we prevented or limited access to our company is an apparent attempt to disparage our company and we deem it both unprofessional and an unfair statement.
Given that we are a medical clinic that does not manufacture drugs, the guidance document that you referenced does not apply to our facility. Instead, USCC is performing a medical procedure wherein tissue is removed from a patient and re-implanted during the same surgical procedure. 21 C.F.R. § 1271(b) titled “Human Cells, Tissues and Cellular Tissue-Based Products,” expressly states, “you are not required to comply with the requirements of this part if you are an establishment that removes HCT/P’s from an individual and implants such HCT/P’s into the same individual during the same surgical procedure.”
The procedure performed at USSC is simply the practice of medicine. Medical practitioners have been performing similar type procedures in clinic for decades including fat, skin, tendon/ligament, vascular, hair and bone grafts, bone marrow transplantation, and blood/plasma transplantation. Please keep in mind that many of these medical procedures may involve non-homologous use of tissue (CABG with vein graft or ileum to replace bladder) or more than minimal manipulation (skin grafts, hair transplants, or bone grafts). But because these are completed by medical practitioners during the same surgical procedure, the practitioners per the exception clause “are not required to comply with the requirements of this part (1271)” which includes details on products under section 351 vs. 361 PHS Act.
Therefore, the regulatory sections of Part 1271 regarding “homologous use” or “more than minimal manipulation” are not applicable to the procedures performed by USSC. To be clear, the purpose of stem cells inside our bodies is to maintain and repair damaged tissue, therefore any application of stem cells to patients would in fact be defined as homologous.
Even if USSC were somehow subject to the regulatory sections of Part 1271, the protocols utilized by USSC would be exempt from the regulations because the procedures practiced at USSC do not involve more than “minimal manipulation.” Part 1271 Regulations create a regulatory exemption from the manufacturing and labeling requirements that normally apply to drugs and biological products for any HCT/P that is no more than “minimally manipulated.” See 21C.F.R.§ 1271.10(a). “Minimal manipulation” of cells means “processing that does not alter the-relevant biological–characteristics.” Id. § 1271.3(f)(2).
In the procedures performed at USCC, the actual stem cells are not modified or changed in any way but instead separated via centrifugation. Even the collagenase digestion only changes the integrity of the extracellular matrix and does not change the characteristics of the cells themselves. These scientific facts were confirmed by several leading stem cell scientists at the September 2016 FDA hearing.
Medical procedures are already scrutinized and regulated by the state medical boards, legislatures, and agencies. In addition, the doctor patient relationship is protected and physicians take a vow to protect the safety, health and welfare of patients. They are dedicated to serving the interest of the patient and market forces, societal pressures, and administrative demands must not compromise this promise. The FDA is responsible for protecting the public health by assuring the safety, efficacy and security of drugs. The FDA does not regulate the practice of medicine or the bodies/tissues of individuals.
This same procedure is currently performed at thousands of clinics throughout the US. Notably, throughout the stem cell field, these clinics and practitioners also maintain that the procedures performed are medical procedures, and that the regulations of part 210 and 211 (current good manufacturing practices) do not apply.
We are aware that many clinics have been visited by the FDA without any actions or warnings letters. At USCC, we are following standard clinical procedures for medical facilities to ensure safety of the patients. This is considered a medical procedure because the tissue is removed from the patient and re-implanted during the same surgical procedure to the same patient (autologous use). The protocols used at our clinic have been well established in publications as both efficacious and safe. Over ten thousand patients have been treated using similar protocols with a strong safety record. Specifically, over 7000 patients have been treated using the exact same laboratory kit that we utilize at USCC.
Bone marrow and blood products are currently being utilized in the clinic in a similar fashion. The only reason bone marrow products are being regulated differently is because they predate the 1976 medical device amendments allowing for a 510k process instead of IND/IDE. There is no scientific or medical reason that fat tissue removed from a patient would be regulated differently than bone marrow or blood, when they are being used for the same purpose. According to recent publications, cells from fat tissue are demonstrating superior clinical results than bone marrow cells. This is most likely due to the fact that the bone marrow contains very high amounts of white blood cells (WBCs) which can cause unnecessary inflammation whereas fat has low amounts of WBCs. Fat tissue, however, may contain up to 500 times more stem cells. The rate of complications from taking a bone marrow aspirate is significantly higher than taking an adipose sample. The cells that are obtained from an adipose sample are separated from the adipocytes and have not been manipulated or changed in any way prior to reintroducing into a patient. According to reports, these therapies do not have the same negative side effects as many of the available drugs on the market.
We are aware that the FDA received comments on the published draft guidelines regarding adipose tissue procedures in clinic. We are also aware that the FDA held a public hearing regarding these topics in September 2016 in which many scientists, physicians and patients expressed support for these therapies. We are able to provide the FDA with any necessary information to demonstrate that this is a medical procedure that is safely done on an outpatient basis. Published results of outcomes to date have been overwhelmingly positive.
If the federal government were to interfere with a person’s ability to obtain and utilize their own cells in their body to heal themselves, this could be a gross violation of the constitution. According to the constitution, Americans have a fundamental right to privacy as well as protection from undue government intrusion. Specifically, in the case of Griswold v. Connecticut 381 U.S. 479, 484-486 (1965), the Supreme Court recognized that “specific guarantees in the Bill of Rights” create “zones of privacy” to protect certain intimate activities from “means which sweep unnecessarily broadly and thereby invade the area of protected freedoms.” Regarding bodily integrity, the court ruled that “no right is held more sacred, or is more carefully guarded…than the right of every individual to the possession and control of his own person, free from all restraint or interference from others…” Both Roe v. Wade, 410 U.S. 113 (1973) and Planned Parenthood v. Casey 506 U.S. 833 (1992), protected rights to privacy, autonomy, and personal choice. See also A.L.A. v. West Valley City, 26 F.3d 989, 990 (10th Cir.1994) (“There is no dispute that confidential medical information is entitled to constitutional privacy protection.”); According to A. Rahman Ford, JD, PhD, “Undue infringement by the federal government upon so sacrosanct a right as the bodily integrity of private persons must be viewed as paternalistic, Victorian and an affront to the freedoms inherent in the Constitution itself.”
Notwithstanding the above—and again, in an abundance of caution—it is our sincerest interest to adhere to the FDA’s interpretation of the laws and have several specific questions that we would like the FDA to kindly provide answers to:
1.Why would bone marrow in-clinic procedures be regulated differently than fat and/or stromal vascular fraction?
2.Is fat which has been mechanically broken down (i.e. the LipoGems procedure) instead of enzyme digestion regulated differently?
3.Will you allow clinics who are using bone marrow to continue to treat patients?
4.Will you restrict the type of patients who are being treated using in-clinic protocols with bone marrow?
5.Will you restrict the discretion of physicians on patient selection to treat using their own body tissue?
6.Are you intending to limit surgical procedures which have been in practice for decades that involve more than minimal manipulation?
7.Are you intending to limit surgical procedures which have been in practice for decades that involve non-homologous use?
8.Are clinics using fat tissue but not using enzyme permitted to operate?
9.Why is the FDA viewing a patient’s own body tissue used in clinic as a drug – please show specific case law justifying this violation of human rights?
10.Why has the FDA visited similar clinics and not taken action?
11.Why is the FDA ignoring the requests of tens of thousands of citizens to keep these therapies available?
12.After the FDA hearing in September 2016 where scientists, physicians and patients spoke out in favor of these therapies, why has the FDA not responded?
Our clinic is simply providing medical treatments to consenting patients using cells from their own body during a medical procedure which does not invoke oversight by the federal government. We would like to specifically request a meeting with the FDA commissioner to better explain the procedures that have successfully helped thousands of people.
We look forward to your responses to our questions above. Feel free to contact me if additional information is required.
Sincerely,
US Stem Cell Clinic
Kristin Comella, CSO
Email: kcomella@us-stemcell.com
Syzygenic...I appreciate your comments. I stay on the side and try to avoid getting pulled down in the mire regarding PMCB. Of all the stocks I own, this one is the ABSOLUTE LEAST of my worries. I personally know one of the executives in this company. If he is "in", then I am "in" all the way.
Going back to the bleachers now.
GLTY
SLAM
$APPZ$ IS ALIVE AND KICKING.....HIGH HIGH HIGH VOLUME
OTC Knight...glad to see you here. Since I'm a novice...if the entire float was traded today...what happens next???
GLTY
SLAM
Who would have thought there was any life remaining here??? Not me, but I'm enjoying the show.
GLTA
SLAM
Pete/Mick...is APPZ coming back to life???
Thoughts??
SLAM
$APPZ$ COULD IT REALLY BE HAPPENING????
SLAM
$APPZ$ IS FINALLY COMMING ALIVE AGAIN....
SLAM
Thanks for staying after this...nice to see some life here again.
SLAM
Change just POSTED
What's your take Pistol$$$$$$
SLAM
$GAWK$ SERVICE UPDATE$$$$
GAWK ANNOUNCED IT'S 3rd Generation Voice Broadcast Engine Zooms Past 10,000 Calls Per Minute...AND CLIMING JUST LIKE THEIR OTHER REVENUE PRODUCING STREAMS$$$$$$
$GAWK$
GAWK 3rd Generation Voice Broadcast Engine Zooms Past 10,000 Calls Per Minute
GAWK Gives Away Cloud Servers to New Customers
LOS ANGELES, CA--(Marketwired - Jun 27, 2017) - GAWK, Inc. (OTC PINK: GAWK) a cloud-based infrastructure-as-a-service company, today announced it is celebrating America's 241st birthday by giving away Cloud Servers, free for the first Three months, to new customers who sign up for a year.
Aimed at small-to-medium businesses and corporate customers, Scott Kettle, CEO of GAWK, said, "We are an entrepreneurial company, and today through July 4th, we salute American Small Business by offering a cloud server, at no cost for three months, to acknowledge the role of small businesses in building our economy. The first 241 Business owners who notify the Company, using the promotional code, 'Independence,' will receive a cloud server free for three months."
The Company is completing its audit, and is undertaking Due Diligence on three possible acquisitions. GAWK acquired four companies that grew its revenue from zero to a present run rate of over $7 million.
WebRunners Inc. provides hosting, cloud, and information technology (IT) services to businesses in the United States and internationally. It offers enterprise-level hosting solutions, including colocation, private clouds, and dedicated and virtual servers. The company also provides virtualization, storage, networking configurations, and virtual desktops/terminal services. In addition, it offers wireless networking, windows domains, Voice Over IP, IP video surveillance, data center design, IT security, IT strategy and governance, upgrade/migration planning, and Microsoft exchange services, as well as support services. WebRunners Inc. was founded in 1998 and is based in Irvine, California. It has data centers locations in Los Angeles and Irvine. WebRunners Inc. operates as a subsidiary of Gawk Incorporated. As of October 30, 2014, WebRunners Inc. operates as a subsidiary of Gawk Incorporated.
xtelus LLC operates a digital network that provides wholesale and retail communications services. It offers voice termination products and solutions for carriers and service providers, mobile operators, MSO’s, VoIP providers, and next generation service providers; and long-distance services for enterprises. The company was incorporated in 2015 and is headquartered in Wake Forest, North Carolina. As of June 27, 2016, Xtelus S.A. operates as a subsidiary of Gawk Incorporated.
Xtelus S.A. operates a digital network which provides wholesale and retail communications services. The company is headquartered in Dominican Republic. As of June 27, 2016, Xtelus S.A. operates as a subsidiary of Gawk Incorporated.
Net D Consulting, Inc. provides telecom services to businesses of various sizes. It offers wholesale; NOC; call center; wireless data; reverse telemarketing for advertisers, as well as for telecom carriers to discover a way to monetize incomplete calls; and trunking services. The company was founded in 2005 and is headquartered in Las Vegas, Nevada. It also has offices in California and India. As of May 1, 2015, Net D Consulting, Inc. operates as a subsidiary of Gawk Incorporated.
Connexum LLC operates as a telecommunications carriers in the United States. It offers wholesale services, including wholesale sip termination, call center termination, wholesale DID origination, and business Internet services; and business services, such as hosted PBX, as well as phones and hardware that include analog adapters, conference stations, expansion modules, and headsets through an online store. The company also operates a telecom agent program that provides its partners with telecommunications products and services with pricing tools, online commission tracking, and the wholesale VoIP support they need to identify and close sip termination/call center termination business. Connexum LLC is based in Irvine, California. As of January 18, 2016, Connexum LLC operates as a subsidiary of Gawk Incorporated.
I'm with you m1...undervalued with some potential. Anyone that plays with pennies without doing their homework shouldn't be here anyway.
GLTY
SLAM
Received...yep still in...and congrats!!!
SLAM
Thanks for the follow-up Big M!!! Don't worry about the writing...a AM from here and mine can be horrible on any given day. Anyway, I appreciate you taking the time to do this for us just have you have done many times in the past. You are a true friend...even being a long distance away.
Best of luck to you my friend.
SLAM
$GAWK$
"GAWK now completing well over 10,000,000 calls a day"
Received...GLTY as well. Looking for a run of a few points shortly on this one...and much more over on **OR.
SLAM
Bar Chart:
Overall Average:
40% Buy
Last week...32% Sell.
Nice swing on the strength indicator as well.
GLTA
SLAM
$GAWK$ STARTING TO MOVE!!!
GAWK Releases 3rd Generation Voice Broadcast Engine
LOS ANGELES, CA--(Marketwired - May 10, 2017) - GAWK, Inc. (OTC PINK: GAWK) a cloud-based infrastructure-as-a-service company, today announced the first commercial deployment of its Voice Broadcast Engine (VB 3.0) platform.
"VB 3.0 introduces several new features which propel our solution to the leader of the pack of voice broadcast technologies," said Scott Kettle, GAWK CEO. Some of these features include Paired Location, Selectable Call Times, Unique Transfer Numbers and Simple Surveys & Polling.
Chris Hall, GAWK President commented, "Our customers are already seeing a significant increase in their call transfer rate, which translates to more sales!" The new VB 3.0 builds upon the years of GAWK experience in the industry to create the most reliable, scalable and feature rich platform in the class.
Kettle further stated, "With GAWK now completing well over 10,000,000 calls a day our VB 3.0 engine has the horsepower to continue our rapid growth while providing a unique feature rich scalable platform. Coupled with our Direct Delivery ™ service... VB 3.0 creates a powerful marketing system in a cost effective manner in which our customers rely upon to fuel their sales."
For investor inquiries please call (888) 754-6190 Ext. 3 or email IR@gawk.com
For more information about GAWK's OTC Markets publicly traded shares click here
About GAWK, Inc.
GAWK, Inc., offers a suite of cloud communications, cloud connectivity, cloud computing, and managed cloud-based applications solutions to small, medium, and large businesses; and offers domestic and international voice services to communications carriers worldwide. It offers a suite of advanced data center and cloud-based services, including fault tolerant, high availability cloud servers, which comprise platform as a service, infrastructure as a service, and a content delivery network; managed network services that converge voice and data applications, structured cabling, wireless, and security services, as well as include Internet access via Ethernet or fiber at speeds ranging from 10 Mbps to 10 Gbps; and data center solutions, including cloud services, colocation services, and business continuity services, such as storage and security. www.gawk.com
Forward-Looking Statements
All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on GAWK's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause GAWK's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; GAWK's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of telecommunications. These factors and others are described in more detail in GAWK's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in GAWK's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on GAWK's website (www.gawk.com) under the heading "Investor Relations." GAWK is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Contact:
GAWK, Inc.
Investor Relations
888.754.6190 Ext. 3
IR@gawk.com
News Provided by QuoteMedia.
$GAWK$ Releases 3rd Generation Voice Broadcast Engine
LOS ANGELES, CA--(Marketwired - May 10, 2017) - GAWK, Inc. (OTC PINK: GAWK) a cloud-based infrastructure-as-a-service company, today announced the first commercial deployment of its Voice Broadcast Engine (VB 3.0) platform.
"VB 3.0 introduces several new features which propel our solution to the leader of the pack of voice broadcast technologies," said Scott Kettle, GAWK CEO. Some of these features include Paired Location, Selectable Call Times, Unique Transfer Numbers and Simple Surveys & Polling.
Chris Hall, GAWK President commented, "Our customers are already seeing a significant increase in their call transfer rate, which translates to more sales!" The new VB 3.0 builds upon the years of GAWK experience in the industry to create the most reliable, scalable and feature rich platform in the class.
Kettle further stated, "With GAWK now completing well over 10,000,000 calls a day our VB 3.0 engine has the horsepower to continue our rapid growth while providing a unique feature rich scalable platform. Coupled with our Direct Delivery ™ service... VB 3.0 creates a powerful marketing system in a cost effective manner in which our customers rely upon to fuel their sales."
For investor inquiries please call (888) 754-6190 Ext. 3 or email IR@gawk.com
For more information about GAWK's OTC Markets publicly traded shares click here
About GAWK, Inc.
GAWK, Inc., offers a suite of cloud communications, cloud connectivity, cloud computing, and managed cloud-based applications solutions to small, medium, and large businesses; and offers domestic and international voice services to communications carriers worldwide. It offers a suite of advanced data center and cloud-based services, including fault tolerant, high availability cloud servers, which comprise platform as a service, infrastructure as a service, and a content delivery network; managed network services that converge voice and data applications, structured cabling, wireless, and security services, as well as include Internet access via Ethernet or fiber at speeds ranging from 10 Mbps to 10 Gbps; and data center solutions, including cloud services, colocation services, and business continuity services, such as storage and security. www.gawk.com
Forward-Looking Statements
All statements in this release that are not strictly historical facts are "forward-looking statements." Such forward-looking statements are based on GAWK's current assumptions, beliefs and expectations, and involve risks, uncertainties and other factors that may cause GAWK's actual results to be materially different from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words such as "expect," "plan," "possibility," "offer," "if," "negotiate," "when," "believe," "will," "estimate," "continue," and similar expressions. Risks, uncertainties, and other factors that could cause or contribute to such differences include, but are not limited to: ongoing and future intellectual property enforcement actions; the ability to successfully litigate or settle claims of patent infringement; GAWK's ability to obtain necessary financing, generate sufficient cash flow, and maintain appropriate indebtedness; and the increasing development of market competition in the area of telecommunications. These factors and others are described in more detail in GAWK's public filings with the Securities and Exchange Commission, including the risks discussed in the "Risk Factors" section in GAWK's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of these reports can be found on GAWK's website (www.gawk.com) under the heading "Investor Relations." GAWK is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Contact:
GAWK, Inc.
Investor Relations
888.754.6190 Ext. 3
IR@gawk.com
News Provided by QuoteMedia.
Big M...Nice to see you here.
Best of all regards,
SLAM
Win some, lose some...but I do find it interesting that NOBODY FLINCHED.
NEW 8K FILED.....
FYI - USRM - BUY
Is U.S. Stem Cell Inc. (USRM) a Buy According to the Charts?
Pearson Staff Writer | April 4, 2017
U.S. Stem Cell Inc. (OTHER OTC:USRM) has been identified by TrendSpotter as a Buy through it’s algorithm-driving system which takes into account a stock’s momentum, volatility and wave theory to arrive at a Buy, Sell or Hold signal.
Taking a deeper dive, it’s important to note that U.S. Stem Cell Inc. (OTHER OTC:USRM)’s trend strength is Maximum. This is based on a scale where Minimum is the weakest signal and Maximum is considered the strongest signal. The direction of the “Buy” trend is Strongest.
In looking at several other indicators we can see that the 7-day Average Directional Indicator is revealing a “Buy” signal. This is a short-term measure used to help identify a stock’s trend. Trading in the direction of a trend can help identify potential risk and ideally increase potential profit. An ADX reading of above 25 suggests a Strong Trend. A reading of 50-75 would indicate a very strong trend and a reading above 75 would be interpreted as the trend being extremely strong (in either direction).
Moving to Bollinger signal’s we note that the 20-day Bollinger signal from 20-day bands stands at Buy for U.S. Stem Cell Inc. (OTHER OTC:USRM). This is another short-term indicator intended to identify overbought and oversold territory as well as to confirm divergences between prices and indicators and to project a future price target for the stock. The Bollinger Buy signal is registered as “Strongest”. The directional signal reveals whether a Buy trend is strengthening or weakening or if a Hold signal is moving towards a Buy or Sell trend.
Another short-term momentum indicator we’ll highlight here is the The 10-8 HiLo Moving Average signal. This is derived from the 10-8 moving average Hilo Channel which is pointing to a Buy trend for U.S. Stem Cell Inc.. Looking a bit further out we can see that the 20-15 Day MACD Oscillator is pointing to a Buy trend.
In trying to get an idea of whether U.S. Stem Cell Inc. (OTHER OTC:USRM) is preparing for a big move, we’ll look at the Weighted Alpha. The Weighted Alpha for U.S. Stem Cell Inc. stands at -85.66, which measures how much a stock has moved up or down over the past year, while putting an emphasis on more recently activity. The Standard Deviation currently stands at +1.37 which measures the current variability of return.
Good morning surfkast...so how do I read that info? Im not familiar with the shorting process.
Thanks in advance for the education.
SLAM
You are absolutely right!!! Also when you come up to a STOP sign, there is nothing printed there to tell you to GO...bwahhhhh
Hey Pete...any thoughts here???
Thanks,
SLAM
GAWK Awarded Trademark for Direct Delivery Product
LOS ANGELES, CA--(Marketwired - Mar 29, 2017) - Gawk Inc. (OTC PINK: GAWK), a cloud-based infrastructure-as-a-service company, today announced it has received trademark protection from the USPTO for its Direct Delivery ™ ringless voicemail product.
Scott Kettle said, "Direct Delivery™ is voice messaging re-invented and is now our fastest growing product. Purpose-built by our own in-house development team, Direct Delivery™ appeals to both our existing customers and is attracting an entirely new customer base."
"We are excited at the prospects for what I consider to be a very disruptive product in the industry. We have added customers to the platform in a rapid fashion and expect this to grow to 50% of our revenues very quickly," stated Scott Kettle, CEO of GAWK. "It is products like this that will help us 'onshore' call center jobs in a highly competitive call center market worldwide."
GAWK is excited to showcase this revolutionary product, Direct Delivery™, at the upcoming Incompas Conference, April 3-5 in New Orleans. The Conference is an important meeting of top industry players. To learn more about the show please visit: show.incompas.org
For investor inquiries please call (888) 754-6190 Ext. 3 or email IR@gawk.com
To Join Gawk's Investor Email List click here: http://unbouncepages.com/gawk/
GLTA
SLAM
IMO...USRM no longer needs to dilute in order to "keep the doors open". I have been here through the splits and other issues that really took a toll. I believe they are well positioned to blow the doors off, financially speaking.
GLTY
SLAM
Yep...oh, did I mention it is a "BUY"...lol
GLTY
SLAM
Barchart Opinion
Indicator
Opinion
Strength & Direction
Composite Indicator
TrendSpotter
Buy
Short Term Indicators
7 Day Average Directional Indicator
Buy
10 - 8 Day Moving Average Hilo Channel
Buy
20 Day Moving Average vs Price
Buy
20 - 50 Day MACD Oscillator
Buy
20 Day Bollinger Bands
Buy
20 - Day Average Volume: 38,235,324
Average: 100% Buy
Medium Term Indicators
40 Day Commodity Channel Index
Buy
50 Day Moving Average vs Price
Buy
20 - 100 Day MACD Oscillator
Buy
50 Day Parabolic Time
BuyBuy
50 - Day Average Volume: 28,766,625
Average: 100% Buy
Long Term Indicators
60 Day Commodity Channel Index
Buy
100 Day Moving Average vs Price
Buy
50 - 100 Day MACD Oscillator
Buy
100 - Day Average Volume: 16,207,115
Average: 100% Buy